Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation.

Meyer, Sara C.; O'Meara, Alix; Buser, Andreas S; Tichelli, André; Passweg, Jakob R; Stern, Martin (2013). Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biology of blood and marrow transplantation, 19(3), pp. 440-444. Elsevier 10.1016/j.bbmt.2012.10.012

[img] Text
1-s2.0-S1083879112004284-main.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (223kB)

In patients referred for allogeneic hematopoietic stem cell transplantation (HSCT), iron overload is frequent and associated with increased morbidity and mortality. Both the evolution of iron overload after transplantation and its correlation with late posttransplantation events are unknown. We studied 290 patients undergoing myeloablative allogeneic HSCT between 2000 and 2009. Serum ferritin, transferrin saturation, transferrin, iron, and soluble transferrin receptor were determined regularly between 1 and 60 months after HSCT, and values were correlated with transplantation outcome. Ferritin levels peaked in the first 3 months posttransplantation and then decreased to normal values at 5 years. Transferrin saturation and iron behaved analogously, whereas transferrin and soluble transferrin receptor increased after an early nadir. Landmark survival analysis showed that hyperferritinemia had a detrimental effect on survival in all periods analyzed (0 to 6 months P < .001; 6 to 12 months P < .001; 1 to 2 years P = .02; 2 to 5 years P = .002). This effect was independent of red blood cell transfusion dependency and graft-versus-host disease. Similar trends were seen for other iron parameters. These data show the natural dynamics of iron parameters in the setting of allogeneic HSCT and provide evidence for a prognostic role of iron overload extending beyond the immediate posttransplantation period. Interventions to reduce excessive body iron might therefore be beneficial both before and after HSCT.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Meyer, Sara Christina

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1083-8791

Publisher:

Elsevier

Language:

English

Submitter:

Julia Elisa Garcia

Date Deposited:

22 Dec 2023 07:08

Last Modified:

22 Dec 2023 07:17

Publisher DOI:

10.1016/j.bbmt.2012.10.012

PubMed ID:

23089566

BORIS DOI:

10.48350/190318

URI:

https://boris.unibe.ch/id/eprint/190318

Actions (login required)

Edit item Edit item
Provide Feedback